Evidence map›Paper›PMID 30302936›Full record

Trial reportJournal of clinical hypertension (Greenwich, Conn.)2018

Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial.

David J Collier, Attila Juhasz, Enrico Agabiti-Rosei, Eric Lloyd, Michie Hisada, Lin Zhao, Stuart Kupfer, Mark J Caulfield

Abstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

David J CollierWilliam Harvey Research Institute & the NIHR Biomedical Research Centre at Barts, Queen Mary University of London, London, UK.ORCID 0000-0003-0866-4058
Attila JuhaszGE Healthcare, Amersham, UK.
Enrico Agabiti-RoseiDepartment of Clinical & Experimental Sciences, University of Brescia, Brescia, Italy.ORCID 0000-0002-6405-5719
Eric LloydTakeda Development Center Americas, Inc, Deerfield, Illinois.
Michie HisadaTakeda Development Center Americas, Inc, Deerfield, Illinois.
Lin ZhaoTakeda Development Center Americas, Inc, Deerfield, Illinois.
Stuart KupferTakeda Pharmaceuticals International, Deerfield, Illinois.
Mark J CaulfieldWilliam Harvey Research Institute & the NIHR Biomedical Research Centre at Barts, Queen Mary University of London, London, UK.ORCID 0000-0001-9295-3594

Funding

Department of Health
6 · The paper itself

Abstract

Patients with grade 2-3 essential hypertension and postplacebo mean clinic systolic blood pressure (SBP) 160-190 mm Hg and 24-hour SBP 140-175 mm Hg by ambulatory blood pressure monitoring (ABPM) received 40 mg azilsartan medoxomil (AZL-M) monotherapy for 4 weeks. "Nonresponders" were then randomized to 8 weeks of double-blind treatment with AZL-M 40 mg, AZL-M/chlortalidone (CLD) 40/25, or AZL-M/CLD 40/12.5 mg. After 8 weeks, mean clinic SBP change was -21.1 (±1.04) mm Hg for AZL-M/CLD 40/25 mg, -15.8 (±1.08) mm Hg for AZL-M/CLD 40/12.5 mg, and -6.4 (±1.05) mm Hg for AZL-M 40 mg (P < 0.001 for both AZL-M/CLD vs AZL-M, ANCOVA). Drug discontinuation rates were 8.9% (AZL-M/CLD 40/25 mg), 7.5% (AZL-M 40 mg), and 3.9% (AZL-M/CLD 40/12.5 mg). Creatinine increased in 8.1% (AZL-M/CLD 40/25), 3.1% (AZL-M/CLD 40/12.5 mg), and 3.0% (AZL-M 40 mg) of patients. AZL-M/CLD was effective and well tolerated in patients not achieving blood pressure targets with AZL-M.

Indexed as

AgedAngiotensin II Type 1 Receptor BlockersBenzimidazolesBlood PressureBlood Pressure Monitoring, AmbulatoryChlorthalidoneDrug Therapy, CombinationEssential HypertensionFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareOxadiazolesSodium Chloride Symporter InhibitorsSystoleAngiotensin II Type 1 Receptor Blockersazilsartan medoxomilBenzimidazolesChlorthalidoneOxadiazolesSodium Chloride Symporter Inhibitorsantihypertensive therapyclinical management of high blood pressure (HBP)clinical trialscombination therapyHypertension-general

Identifiers

PMID30302936
PMCPMC8030929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.